Table 2. IRC- and investigator-assessed... | American Society of Hematology

Table 2.

IRC- and investigator-assessed responses

Response assessment	Investigator-assessed response (N = 32)	IRC-assessed response (N = 32)
ORR 95% CI*	29 (90.6) (75.0-98.0)	27 (84.4) (67.2-94.7)
Best response
CR	10 (31.3)	8 (25.0)
PR	19 (59.4)	19 (59.4)
Stable disease	1 (3.1)	2 (6.3)
PD	2 (6.3)	2 (6.3)
Unknown†	0	1 (3.1)

Response assessment	Investigator-assessed response (N = 32)	IRC-assessed response (N = 32)
ORR 95% CI*	29 (90.6) (75.0-98.0)	27 (84.4) (67.2-94.7)
Best response
CR	10 (31.3)	8 (25.0)
PR	19 (59.4)	19 (59.4)
Stable disease	1 (3.1)	2 (6.3)
PD	2 (6.3)	2 (6.3)
Unknown†	0	1 (3.1)

Unless otherwise noted, data are n (%).

Two-sided Clopper-Pearson 95% CIs.

Patient had discontinued treatment and died before signing an updated informed consent to allow scan collection for IRC review.